NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs NGR-TNF (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors MolMed
- 27 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Dec 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014.
- 20 Dec 2013 MoliMed has enrolled the first patient in Russia in this trial, according to a company media release. The study foresees the enrolment of 100 patients in Europe and Russia by the end of 2014.